Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue
TL;DR: For ovarian tissue from patients with hematologic malignancies, it is of paramount importance to identify minimal residual disease before ovarian tissue transplantation, and these pathologies are considered to be most at risk of ovarian metastasis.
About: This article is published in Fertility and Sterility.The article was published on 2013-05-01. It has received 268 citations till now. The article focuses on the topics: Ovarian tissue cryopreservation & Transplantation.
Citations
More filters
TL;DR: The present review reports the results of 60 orthotopic reimplantations of cryopreserved ovarian tissue performed by three teams, as well as 24 live births reported in the literature to date, finding Restoration of ovarian activity occurred in almost all cases in the three series.
463 citations
TL;DR: Fertility preservation needs to be completed before chemotherapy and/or irradiation is started and might take 2–3 weeks with established techniques such as embryo or oocyte cryopreservation, but further studies are needed in patients with cancer to confirm the excellent outcomes obtained in patients without cancer or in egg donation programmes.
Abstract: In women, ∼10% of cancers occur in those 90% of girls and young women with diseases that require such treatments. However, these treatments can result in premature ovarian failure, depending on the follicular reserve, the age of the patient and the type and dose of drugs used. This article discusses the different fertility preservation strategies: medical therapy before chemotherapy; ovarian transposition; embryo cryopreservation; oocyte vitrification; and ovarian tissue cryopreservation. The indications, results and risks of these options are discussed. Whether medical therapy should be used to protect the gonads during chemotherapy remains a source of debate. Fertility preservation needs to be completed before chemotherapy and/or irradiation is started and might take 2-3 weeks with established techniques such as embryo or oocyte cryopreservation. Further studies are needed in patients with cancer to confirm the excellent outcomes obtained in patients without cancer or in egg donation programmes. For prepubertal girls or cases where immediate therapy is required, cryopreservation of ovarian tissue is the only available option. Finally, possible future approaches are reviewed, including in vitro maturation of nonantral follicles, the artificial ovary, oogonial stem cells and drugs to prevent follicle loss.
359 citations
University of Edinburgh1, Netherlands Cancer Institute2, The Catholic University of America3, Radboud University Nijmegen4, University Hospital of Wales5, Leiden University6, Université libre de Bruxelles7, University of Liverpool8, University of Genoa9, University of Coimbra10, Karolinska University Hospital11, Karolinska Institutet12
TL;DR: The ESHRE Guideline on Female Fertility Preservation provides clinicians with clear advice on best practice in female FP, based on the best evidence currently available, and a list of research recommendations is provided to stimulate further studies in FP.
Abstract: STUDY QUESTION
What is the recommended management for women and transgender men with regards to fertility preservation (FP), based on the best available evidence in the literature?
243 citations
TL;DR: Development of this specialty needs better provision of information for patients and their medical teams, and improvements in service provision, to match technical and scientific advances.
223 citations
Roswell Park Cancer Institute1, University of Alabama at Birmingham2, Harvard University3, University of California, Los Angeles4, Oregon Health & Science University5, St. Jude Children's Research Hospital6, Oncology Nursing Society7, Memorial Sloan Kettering Cancer Center8, Livestrong Foundation9, Centers for Disease Control and Prevention10, National Institutes of Health11
TL;DR: Workshop participants identified many gaps and challenges in the care of AYA cancer patients and discussed potential strategies to address these needs, and suggested ways to improve access to care for AYAs and deliver cancer care that better meets the medical and psychosocial needs of A YAs.
Abstract: Cancer is the leading disease-related cause of death in adolescents and young adults (AYAs). This population faces many short- and long-term health and psychosocial consequences of cancer diagnosis and treatment, but many programs for cancer treatment, survivorship care, and psychosocial support do not focus on the specific needs of AYA cancer patients. Recognizing this health care disparity, the National Cancer Policy Forum of the Institute of Medicine convened a public workshop to examine the needs of AYA patients with cancer. Workshop participants identified many gaps and challenges in the care of AYA cancer patients and discussed potential strategies to address these needs. Suggestions included ways to improve access to care for AYAs, to deliver cancer care that better meets the medical and psychosocial needs of AYAs, to develop educational programs for providers who care for AYA cancer survivors, and to enhance the evidence base for AYAs with cancer by facilitating participation in research.
210 citations
References
More filters
TL;DR: The BIOMED-2 multiplex tubes can now be used for diagnostic clonality studies as well as for the identification of PCR targets suitable for the detection of minimal residual disease.
Abstract: In a European BIOMED-2 collaborative study, multiplex PCR assays have successfully been developed and standardized for the detection of clonally rearranged immunoglobulin (Ig) and T-cell receptor (TCR) genes and the chromosome aberrations t(11;14) and t(14;18). This has resulted in 107 different primers in only 18 multiplex PCR tubes: three VH-JH, two DH-JH, two Ig kappa (IGK), one Ig lambda (IGL), three TCR beta (TCRB), two TCR gamma (TCRG), one TCR delta (TCRD), three BCL1-Ig heavy chain (IGH), and one BCL2-IGH. The PCR products of Ig/TCR genes can be analyzed for clonality assessment by heteroduplex analysis or GeneScanning. The detection rate of clonal rearrangements using the BIOMED-2 primer sets is unprecedentedly high. This is mainly based on the complementarity of the various BIOMED-2 tubes. In particular, combined application of IGH (VH-JH and DH-JH) and IGK tubes can detect virtually all clonal B-cell proliferations, even in B-cell malignancies with high levels of somatic mutations. The contribution of IGL gene rearrangements seems limited. Combined usage of the TCRB and TCRG tubes detects virtually all clonal T-cell populations, whereas the TCRD tube has added value in case of TCRgammadelta(+) T-cell proliferations. The BIOMED-2 multiplex tubes can now be used for diagnostic clonality studies as well as for the identification of PCR targets suitable for the detection of minimal residual disease.
2,902 citations
Book•
01 Apr 1995TL;DR: The author examines the immune system through the lens of Epstein-Barr Virus-Associated Diseases, as well as the biology of Stem Cells and Disorders of Hematopoiesis, and the approach to the Adult and Child with Anemia.
Abstract: Part I: Mollecular and Cellular Basis of Hematology. Anatomy and Physiology of the Gene. Protein Synthesis and Intracellular Sorting. Protein Architecture: Relationship of Form and Function. Membrane Biology. Cell Adhesion. Cellular Regulatory and Control Mechanism. Part II: Immunologic Basis of Hematology. Overview of the Immune System (including Compartmentalization of the Immune Response). Generation of B-cells. T-cell Immunity. Regulation of Activation of B and T-cells. Tolerance and Autoimmunity. Part III: Biology of Stem Cells and Disorders of Hematopoiesis. Stem Cell Model of Hematopoiesis. Anatomy and Physiology of Hematopoiesis. Growth Factors and the Control of Hematopoiesis. Biology of Erythropoiesis, Erythroid Differentiation and Maturation. Granulopoiesis and Monocytopoiesis. Thrombocytopoiesis. Inherited Forms of Bone Marrow Failure. Aplastic Anemia. Paroxysmal Nocturnal Hemoglobinuria. Pure Red Blood Cell Aplasia. Part IV: Red Blood Cells. Pathobiology of the Red Cell. Approach to the Adult and Child with Anemia. Anemia of Chronic Diseases. Erythrocytosis. Disorders of Iron Metabolism: Iron Deficiency and Overload. Heme Biosynthesis and Its Disorders: Porphyrias and Sideroblastic Anemias. Megaloblastic Anemias. Thalassemia Syndromes. Sickle Cell Disease. Hemoglobin Variants Associated with Hemolytic Anemia, Altered Oxygen Affinity, and Methemoglobinemias. Enzymopathies. Red Cell Membrane Disorders. Autoimmune Hemolytic Anemias. Extrinsic Nonimmune Hemolytic Anemias. Part V: Host Defense and Its Disorders. Immunoglobulins: Structure, Function, and Uses. Complement Biology. Neutrophil Structure and Function. Monocyte and Macrophage Development and Function. Eosinophils and the Hypereosinophilic Syndrome. Disorders of the Phagocyte Function. Disorders of the Lymphocyte Function. Histiocytic Syndromes. Lysosomal Storage Disease. Infectious Mononucleosis and Other Epstein-Barr Virus-Associated Diseases. Spleen and Its Disorders. Systemic Mastocytosis. Part VI: Hemat
1,646 citations
"Risk of transferring malignant cell..." refers background in this paper
...Recurrent chromosome translocations are reported in 38% of ALL patients (15, 16)....
[...]
TL;DR: The development of standardized protocols for RQ-PCR analysis of FG transcripts provides a milestone for molecular determination of MRD levels and is likely to prove invaluable to the management of patients entered into multicenter therapeutic trials.
Abstract: Detection of minimal residual disease (MRD) has proven to provide independent prognostic information for treatment stratification in several types of leukemias such as childhood acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and acute promyelocytc leukemia. This report focuses on the accurate quantitative measurement of fusion gene (FG) transcripts as can be applied in 35-45% of ALL and acute myeloid leukemia, and in more than 90% of CML. A total of 26 European university laboratories from 10 countries have collaborated to establish a standardized protocol for TaqMan-based real-time quantitative PCR (RQ-PCR) analysis of the main leukemia-associated FGs within the Europe Against Cancer EAC) program. Four phases were scheduled: (1) training, (2) optimization, (3) sensitivity testing and (4) patient sample testing. During our program, three quality control rounds on a large series of coded RNA samples were performed including a balanced randomized assay, which enabled final validation of the EAC primer and probe sets. The expression level of the nine major FG transcripts in a large series of stored diagnostic leukemia samples (n = 278) was evaluated. After normalization, no statistically significant difference in expression level was observed between bone marrow and peripheral blood on paired samples at diagnosis. However, RQ-PCR revealed marked differences in FG expression between transcripts in leukemic samples at diagnosis that could account for differential assay sensitivity. The development of standardized protocols for RQ-PCR analysis of FG transcripts provides a milestone for molecular determination of MRD levels. This is likely to prove invaluable to the management of patients entered into multicenter therapeutic trials.
1,450 citations
TL;DR: The findings suggest that cryopreservation of ovarian tissue should be offered to all young women diagnosed with cancer and a livebirth after orthotopic autotransplantation of Cryopreserved ovarian tissue is described.
1,449 citations